PLRX

Pliant Therapeutics Inc. (PLRX) | Rumor.io

Pliant Therapeutics

PLRX

Attention (50-day avg)0%

Attention rank (50-day avg)#3,534

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.45

Market capitalization66.9M

Earnings per share-1.51

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-149.3M

Social

What share of all stock conversation is about PLRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% +0

Dec 4

$PLRX is trading at a significant discount to its cash per share, with some investors considering it a buy opportunity.
Pliant Therapeutics has announced interim data from its PLN-101095 drug trial, showing a median time on treatment of 15 months for responders, with plans for a Phase 1b expansion in 2026.
The company has a strong cash position, with $240 million in cash and a market capitalization of $90 million, leading some to speculate about the potential for a price increase.

Generated by AI

Sentiment

Of the messages about PLRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100%	92.41% +19.58
Bearish	—	0%	0%	7.59% -19.58

Bullish· Oct 21

Pliant Therapeutics, Inc. (PLRX) has a high cash position, with $264.4 million as of June 30, 2025, making it an undervalued play compared to its market cap.
The company is expected to release its third-quarter 2025 financial results around November 6, 2025, which may include updates on its cash runway, operational changes, and progress on remaining pipeline assets.
PLRX has seen significant call buying, particularly at $2.50, which could indicate a potential transaction or distribution, and may be setting up for a move to $5 per share or higher on positive results.

Bearish· Feb 10

Pliant Therapeutics, Inc. ($PLRX) has paused enrollment and dosing in its BEACON-IPF trial due to a Data and Safety Monitoring Board (DSMB) recommendation.
Analysts have downgraded the stock, cutting price targets from $40+ to $4, citing uncertainty and safety concerns following the trial pause.
The stock's price may be poised to drop further, with some predicting it could fall to $2 or below.

Generated by AI

Topics

Of the messages about PLRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	53.75%
Analysts	—	—	—	9.38%
Controversies	—	—	—	4.38%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	32.5%

Announcements· Jan 25

Pliant Therapeutics, Inc. (PLRX) has priced an upsized $250.0 million public offering at $30 per share.
The company announced the appointment of Lily Cheung as Chief Human Resources Officer.
Pliant Therapeutics has filed a Form 8-K with the SEC regarding the results of operations and financial condition, as well as other events.

Technical Analysis· Jul 11

The RSI for $PLRX is currently at 90 on the daily chart, indicating overbought conditions.
The stock has broken above its 2022 price levels and is trading above its 200-day moving average, which is a bullish sign.
The stock is showing signs of a potential double top formation, with a possible break below $22.40 and a subsequent consolidation before continuing upward.

Generated by AI

Community

Of the messages about PLRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	40.32%
Newcomers	—	100%	100%	59.68%

Regulars· Sep 26

Pliant Therapeutics, Inc. ($PLRX) announced positive safety and exploratory efficacy data from its Phase 2a INTEGRIS-PSC trial for its lead asset bexotegrast, treating primary sclerosing cholangitis and suspected liver fibrosis.
The trial results led to a significant increase in $PLRX shares, with a 9.75% gain premarket, and a 17.6% surge in the stock price after the announcement.
The company will host an investor call and webcast to discuss the interim results from the INTEGRIS-PSC trial, providing further insights into the trial's findings and the potential of bexotegrast as a treatment for the chronic liver disease.

Newcomers· Oct 21

Pliant Therapeutics, Inc. is expected to release its third-quarter 2025 financial results around November 6, 2025, which may include updates on cash runway and operational changes.
The company has repaid a $32.4 million loan to Oxford Finance LLC, terminating their Loan Agreement, and is projected to have around $210 million in cash as of October, or approximately $3.40 per share.
There is unusual call options volume on strikes for January 2026, with some users anticipating a potential explosive move if the stock breaks above $1.89.

Generated by AI

News

Analysts Offer Insights on Healthcare Companies: Quoin Pharmaceuticals (QNRX) and Pliant Therapeutics (PLRX)

Detailed price information for Quoin Pharmaceuticals Ltd ADR (QNRX-Q) from The Globe and Mail including charting and trades.

1mo agotheglobeandmail.com

Why is Pliant Therapeutics stock climbing today?

1mo agoInvesting.com

Pliant Therapeutics receives FDA fast track for cancer drug

1mo agoInvesting.com

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced the receipt of Fast Track...

1mo agoBarchart.com

RBC Capital Sticks to Their Hold Rating for Pliant Therapeutics (PLRX)

Tipranks Press Release.

1mo agoThe Globe and Mail

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

FORTIFY, a Phase 1b indication expansion trial of PLN-101095, experiencing strong enrollment Appointed seasoned oncology drug development leaders Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported second qu

1mo agoYahoo Finance

Also Discussed

Investors talking about PLRX also mention

#	Name	Attention
1	Nkarta, Inc.NKTX	0%0
2	KSPN - Kaspien Holdings Inc.	——
3	KZR - Kezar Life Sciences, Inc.	——
4	DAWN - Day One Biopharmaceuticals, Inc.	——
5	United Maritime CorporationUSEA	0%0
6	Rhythm Pharmaceuticals, Inc.RYTM	0%0
7	DICE - DICE Therapeutics, Inc.	——
8	PMV Pharmaceuticals, Inc.PMVP	0%0
9	Janux Therapeutics, Inc.JANX	0%0
10	IGMS - IGM Biosciences, Inc.	——

Pliant Therapeutics Inc.

Healthcare
Biotechnology

Pliant Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapies for fibrotic diseases and related conditions. The company’s current pipeline centers on oral and other targeted drug candidates designed to modulate key pathways involved in fibrosis, with programs being studied in areas such as idiopathic pulmonary fibrosis, primary sclerosing cholangitis, liver fibrosis, solid tumors, and muscular dystrophies. Its research platform is built around integrin biology, which plays an important role in cell signaling, tissue remodeling, and disease progression. Pliant Therapeutics Inc. operates as a specialist developer within the biotechnology sector, contributing to the broader market for treatments aimed at serious, chronic, and often underserved diseases.

Website

Location

331 Oyster Point Boulevard

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about PLRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% +0

Dec 4

$PLRX is trading at a significant discount to its cash per share, with some investors considering it a buy opportunity.
Pliant Therapeutics has announced interim data from its PLN-101095 drug trial, showing a median time on treatment of 15 months for responders, with plans for a Phase 1b expansion in 2026.
The company has a strong cash position, with $240 million in cash and a market capitalization of $90 million, leading some to speculate about the potential for a price increase.

Generated by AI

Sentiment

Of the messages about PLRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100%	92.41% +19.58
Bearish	—	0%	0%	7.59% -19.58

Bullish· Oct 21

Pliant Therapeutics, Inc. (PLRX) has a high cash position, with $264.4 million as of June 30, 2025, making it an undervalued play compared to its market cap.
The company is expected to release its third-quarter 2025 financial results around November 6, 2025, which may include updates on its cash runway, operational changes, and progress on remaining pipeline assets.
PLRX has seen significant call buying, particularly at $2.50, which could indicate a potential transaction or distribution, and may be setting up for a move to $5 per share or higher on positive results.

Bearish· Feb 10

Pliant Therapeutics, Inc. ($PLRX) has paused enrollment and dosing in its BEACON-IPF trial due to a Data and Safety Monitoring Board (DSMB) recommendation.
Analysts have downgraded the stock, cutting price targets from $40+ to $4, citing uncertainty and safety concerns following the trial pause.
The stock's price may be poised to drop further, with some predicting it could fall to $2 or below.

Generated by AI

Topics

Of the messages about PLRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	53.75%
Analysts	—	—	—	9.38%
Controversies	—	—	—	4.38%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	32.5%

Announcements· Jan 25

Pliant Therapeutics, Inc. (PLRX) has priced an upsized $250.0 million public offering at $30 per share.
The company announced the appointment of Lily Cheung as Chief Human Resources Officer.
Pliant Therapeutics has filed a Form 8-K with the SEC regarding the results of operations and financial condition, as well as other events.

Technical Analysis· Jul 11

The RSI for $PLRX is currently at 90 on the daily chart, indicating overbought conditions.
The stock has broken above its 2022 price levels and is trading above its 200-day moving average, which is a bullish sign.
The stock is showing signs of a potential double top formation, with a possible break below $22.40 and a subsequent consolidation before continuing upward.

Generated by AI

Community

Of the messages about PLRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	40.32%
Newcomers	—	100%	100%	59.68%

Regulars· Sep 26

Pliant Therapeutics, Inc. ($PLRX) announced positive safety and exploratory efficacy data from its Phase 2a INTEGRIS-PSC trial for its lead asset bexotegrast, treating primary sclerosing cholangitis and suspected liver fibrosis.
The trial results led to a significant increase in $PLRX shares, with a 9.75% gain premarket, and a 17.6% surge in the stock price after the announcement.
The company will host an investor call and webcast to discuss the interim results from the INTEGRIS-PSC trial, providing further insights into the trial's findings and the potential of bexotegrast as a treatment for the chronic liver disease.

Newcomers· Oct 21

Pliant Therapeutics, Inc. is expected to release its third-quarter 2025 financial results around November 6, 2025, which may include updates on cash runway and operational changes.
The company has repaid a $32.4 million loan to Oxford Finance LLC, terminating their Loan Agreement, and is projected to have around $210 million in cash as of October, or approximately $3.40 per share.
There is unusual call options volume on strikes for January 2026, with some users anticipating a potential explosive move if the stock breaks above $1.89.

Generated by AI

Pliant Therapeutics

Social

Dec 4

Bullish· Oct 21

Bearish· Feb 10

Announcements· Jan 25

Technical Analysis· Jul 11

Regulars· Sep 26

Newcomers· Oct 21

Analysts Offer Insights on Healthcare Companies: Quoin Pharmaceuticals (QNRX) and Pliant Therapeutics (PLRX)

Why is Pliant Therapeutics stock climbing today?

Pliant Therapeutics receives FDA fast track for cancer drug

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

RBC Capital Sticks to Their Hold Rating for Pliant Therapeutics (PLRX)

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Also Discussed

Pliant Therapeutics Inc.

Company Information

Location

Analysts Offer Insights on Healthcare Companies: Quoin Pharmaceuticals (QNRX) and Pliant Therapeutics (PLRX)

Why is Pliant Therapeutics stock climbing today?

Pliant Therapeutics receives FDA fast track for cancer drug

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

RBC Capital Sticks to Their Hold Rating for Pliant Therapeutics (PLRX)

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Also Discussed

Social

Dec 4

Bullish· Oct 21

Bearish· Feb 10

Announcements· Jan 25

Technical Analysis· Jul 11

Regulars· Sep 26

Newcomers· Oct 21